Nektar’s Sole Skeptic Warns of Parallels to Biggest Biotech Flop
A long-time skeptic of Nektar Therapeutics on Wall Street remains cautious after Monday’s 42 percent plunge, the worst performance for an S&P 500 Index member in ...
Continue Reading →
